These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 19015956)

  • 21. The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers.
    Kaialy W; Martin GP; Larhrib H; Ticehurst MD; Kolosionek E; Nokhodchi A
    Colloids Surf B Biointerfaces; 2012 Jan; 89():29-39. PubMed ID: 21962946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of milling and sieving on functionality of dry powder inhalation products.
    Steckel H; Markefka P; teWierik H; Kammelar R
    Int J Pharm; 2006 Feb; 309(1-2):51-9. PubMed ID: 16377105
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
    Jetzer MW; Schneider M; Morrical BD; Imanidis G
    J Pharm Sci; 2018 Apr; 107(4):984-998. PubMed ID: 29247741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
    Marriott C; MacRitchie HB; Zeng XM; Martin GP
    Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug.
    Sethuraman VV; Hickey AJ
    AAPS PharmSciTech; 2002; 3(4):E28. PubMed ID: 12916922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The influence of mechanical processing of dry powder inhaler carriers on drug aerosolization performance.
    Young PM; Chan HK; Chiou H; Edge S; Tee TH; Traini D
    J Pharm Sci; 2007 May; 96(5):1331-41. PubMed ID: 17455362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adhesion forces in interactive mixtures for dry powder inhalers--evaluation of a new measuring method.
    Lohrmann M; Kappl M; Butt HJ; Urbanetz NA; Lippold BC
    Eur J Pharm Biopharm; 2007 Sep; 67(2):579-86. PubMed ID: 17418548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immobilization of fine particles on lactose carrier by precision coating and its effect on the performance of dry powder formulations.
    Chan LW; Lim LT; Heng PW
    J Pharm Sci; 2003 May; 92(5):975-84. PubMed ID: 12712417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterisation and deposition studies of recrystallised lactose from binary mixtures of ethanol/butanol for improved drug delivery from dry powder inhalers.
    Kaialy W; Martin GP; Ticehurst MD; Royall P; Mohammad MA; Murphy J; Nokhodchi A
    AAPS J; 2011 Mar; 13(1):30-43. PubMed ID: 21057906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of Granulated Lactose as a Carrier for Dry Powder Inhaler Formulations 2: Effect of Drugs and Drug Loading.
    Du P; Du J; Smyth HDC
    J Pharm Sci; 2017 Jan; 106(1):366-376. PubMed ID: 27939234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of humidity on the electrostatic charge and aerosol performance of dry powder inhaler carrier based systems.
    Young PM; Sung A; Traini D; Kwok P; Chiou H; Chan HK
    Pharm Res; 2007 May; 24(5):963-70. PubMed ID: 17377746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surface Modification of lactose carrier particles using a fluid bed coater to improve fine particle fraction for dry powder inhalers.
    Gong QQ; Tay JYS; Veronica N; Xu J; Heng PWS; Zhang YP; Liew CV
    Pharm Dev Technol; 2023 Feb; 28(2):164-175. PubMed ID: 36683577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The contribution of different formulation components on the aerosol charge in carrier-based dry powder inhaler systems.
    Hoe S; Traini D; Chan HK; Young PM
    Pharm Res; 2010 Jul; 27(7):1325-36. PubMed ID: 20354768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does carrier size matter? A fundamental study of drug aerosolisation from carrier based dry powder inhalation systems.
    Ooi J; Traini D; Hoe S; Wong W; Young PM
    Int J Pharm; 2011 Jul; 413(1-2):1-9. PubMed ID: 21501674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cohesive-adhesive balances in dry powder inhaler formulations II: influence on fine particle delivery characteristics.
    Begat P; Morton DA; Staniforth JN; Price R
    Pharm Res; 2004 Oct; 21(10):1826-33. PubMed ID: 15553229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Formulation and evaluation of insulin dry powder for inhalation.
    Mahesh Kumar T; Misra A
    Drug Dev Ind Pharm; 2006 Jul; 32(6):677-86. PubMed ID: 16885123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterizing the Surface Roughness Length Scales of Lactose Carrier Particles in Dry Powder Inhalers.
    Tan BMJ; Chan LW; Heng PWS
    Mol Pharm; 2018 Apr; 15(4):1635-1642. PubMed ID: 29490144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of surface layering time of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate.
    Iida K; Hayakawa Y; Okamoto H; Danjo K; Luenberger H
    Chem Pharm Bull (Tokyo); 2004 Mar; 52(3):350-3. PubMed ID: 14993760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate.
    Le VN; Bierend H; Robins E; Steckel H; Flament MP
    Int J Pharm; 2012 Jan; 422(1-2):75-82. PubMed ID: 22036653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adhesion and redistribution of salmeterol xinafoate particles in sugar-based mixtures for inhalation.
    Adi H; Larson I; Stewart PJ
    Int J Pharm; 2007 Jun; 337(1-2):229-38. PubMed ID: 17303354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.